381
Participants
Start Date
June 30, 2010
Primary Completion Date
February 28, 2013
Study Completion Date
June 30, 2013
Elacytarabine
Elacytarabine 2000 mg/m2/d administered as a continuous intravenous infusion (CIV) in a d 1-5 q3w cycle.
Investigator's Choice
E.g. cytarabine single agent/combinations, hypomethylating agents, best supportive care (BSC)
Institut Jules Bordet, Brussels
UZ Brussel, Brussels
Royal North Shore Hopsital, Sydney
University Hospital Antwerp, Edegem
Alfred Hospital, Melbourne
Box Hill Hospital, Melbourne
CHU Liège, Liège
Haukeland Universitetssykehus, Bergen
UCL Mont-Godinne, Yvoir
Sir Charles Gairdner Hospital, Perth
St Olavs Hospital, Trondheim
Algemeen Ziekenhuis Sint-Jan, Bruges
New York Presbyterian Hospital, Weill-Cornell Medical College, New York
Memorial Sloan-Kettering, New York
New York Medical College, Valhalla
Charité-Campus B. Franklin Med. Klinik Haematology, Berlin
Institut J. Paoli and I. Calmettes, Marseille
Western Pennsylvania Hospital, Pittsburgh
A.O San Martino, Genova
Universitätsklinikum Rostock, Rostock
Fondazione San Raffaele del Monte Tabor, Milan
Duke University Medical Center, Durham
Hospital Universitario La Princesa, Madrid
St. Francis Hospital, Greenville
Winship Cancer Institute at Emory, Atlanta
The Blood and Marrow Transplant Group of GA, Atlanta
Hospital de Navarra, Pamplona
CHU de Toulouse - Hôpital Purpan, Toulouse
Shands at the University of Florida, Gainesville
CHU de Bordeaux - Hopital Haut-Leveque, Pessac
Hospital Universitario de Salamanca, Salamanca
Sarah Cannon Research Institute, Nashville
Heinrich-Heine Universität Düsseldorf, Klinik für Hämatologie/Onkolog. und Klin. Immunologie, Düsseldorf
The Jewish Hospital, Cincinnati
Hospital Universitario La Fé, Servicio de Hematología, Valencia
St. Francis Hospital and Health Center, Indianapolis
Hospital S. Maria delle Croci, Ravenna
Universitätsklinikum Münster, Medisinische Klinik & Poliklinik A, Münster
A.O.U Careggi, Florence
University of Iowa Hopsitals, Iowa City
Froedtert Hospital, Medical College of Wisconsin, Milwaukee
III. Medizinische Klinik und Poliklinik;Hämatologie, Onkologie und Pneumologie, Mainz
Northwestern University, Chicago
Rush University Medical Center, Chicago
Hopital Edouard Herriot, Lyon
Robert-Bosch-Krankenhaus, Abt.Hämatologie,Onkologie u.Palliativmedizin, Stuttgart
LSU Health Sciences Center,, Shreveport
Hopital Saint Antoine, Paris
A.O. Cardarelli, Napoli
Rocky Mountain Blood and Bone Marrow Transplant Program, Denver
CHU Limoges - Hôpital Dupuytren, Limoges
Universitätsklinikum Ulm, Klinik für Innere Medizin III, Comprehensive Cancer Center Ulm (CCCU), Ulm
USC/Norris Comprehensive Cancer Center and Hospital, Los Angeles
Scripps Cancer Center Clinical Research, La Jolla
UCLA School of Medicine, Division of Hematology/Oncology, Los Angeles
"Oncology Institute ,,Ion Chiricuta Cluj Napoca , Hematology dept.", Cluj-Napoca
"St. Spiridon University Hospital, Hematology Department", Iași
Northern New Jersey Cancer Associates, Hackensack
Wake Forest University, Health Sciences Section on Hematology and Oncology, Winston-Salem
Princess Margaret Hospital, Toronto
Centre Antoine Lacassagne, Nice
Evangelische Kliniken Johanniter- und Waldkrankenhaus Bonn GmbH, Bonn
St James's Hospital Dublin, Dublin
University Hospital Galway, Galway
Fondazion Policlin T Vergata, Roma
Oslo University Hospital, Oslo
Samodzielny Publiczny Szpital Kliniczny Nr 1 we Wroclawiu, Wroclaw
"Fundeni Clinical Institute Stefan Berceanu Center for Hematology and Bone Marrow Transplant", Bucharest
Hospital Germans Trias i Pujol, Badalona
Hospital Universitari Son Dureta, Palma de Mallorca
Gartnavel General Hospital: Beatson WOS Cancer Centre, Glasgow
Bristol Haematology and Oncology Centre, Bristol
Christie Hospital, Haematology and Transplant Day Unit, Manchester
Lead Sponsor
Clavis Pharma
INDUSTRY